Regulators meet in Beijing to balance local with global
This article was originally published in Scrip
With a theme of building global regulatory approaches based on national regulations, the ninth International Summit of Heads of Medicines Regulatory Agencies has been held in China's capital Beijing, despite the city being enveloped with choking air pollution.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.